Mia E. Hofstad

This study shows that dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-deficient prostate cancer cells, with Compound B effectively achieving this in vitro and in vivo.

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.